Positive results from second pivotal phase 3 study of brodalumab in patients with moderate-to-severe plaque psoriasis announced

Amgen and AstraZeneca has announced that AMAGINE-3™, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more (more…)

Read More